KemPharm is a specialty pharmaceutical company focused on the discovery and development of prodrugs to treat serious medical conditions through its Ligand Activated Therapy, or LAT®, technology. Co.'s product candidate pipeline is focused on the areas of attention deficit hyperactivity disorder (ADHD), stimulant use disorder and idiopathic hypersomnia (IH). Co.'s products, AZSTARYS and KP484, are both based on a prodrug of d-methylphenidate, but with differing extended-release effect profiles, and are intended for the treatment of ADHD. Co.'s clinical development product candidate, KP879, is also based on a prodrug of d-MPH. The KMPH stock yearly return is shown above.
The yearly return on the KMPH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KMPH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|